WO2024258870A8 - Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine - Google Patents

Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine

Info

Publication number
WO2024258870A8
WO2024258870A8 PCT/US2024/033443 US2024033443W WO2024258870A8 WO 2024258870 A8 WO2024258870 A8 WO 2024258870A8 US 2024033443 W US2024033443 W US 2024033443W WO 2024258870 A8 WO2024258870 A8 WO 2024258870A8
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
receptor agonist
beta receptor
agonist binding
lymphotoxin beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033443
Other languages
English (en)
Other versions
WO2024258870A2 (fr
Inventor
Rajkumar NOUBADE
Ian Nevin FOLTZ
Hong Yu Wang
Danyang GONG
Ryan Benjamin CASE
Jun Zhang
Chin-Wen Lai
Fernando Garces
Christine Elaine Tinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to KR1020267000619A priority Critical patent/KR20260025131A/ko
Priority to PE2025003091A priority patent/PE20260306A1/es
Priority to CN202480038870.XA priority patent/CN121399157A/zh
Priority to AU2024305352A priority patent/AU2024305352A1/en
Publication of WO2024258870A2 publication Critical patent/WO2024258870A2/fr
Priority to IL325097A priority patent/IL325097A/en
Priority to JOJO/P/2025/0305A priority patent/JOP20250305A1/ar
Publication of WO2024258870A8 publication Critical patent/WO2024258870A8/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2024/033443 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine Pending WO2024258870A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020267000619A KR20260025131A (ko) 2023-06-12 2024-06-11 림포톡신 베타 수용체 작용제 결합 단백질
PE2025003091A PE20260306A1 (es) 2023-06-12 2024-06-11 Proteinas de union a receptor de linfotoxina beta agonistas
CN202480038870.XA CN121399157A (zh) 2023-06-12 2024-06-11 淋巴毒素β受体激动剂结合蛋白
AU2024305352A AU2024305352A1 (en) 2023-06-12 2024-06-11 Lymphotoxin beta receptor agonist binding proteins
IL325097A IL325097A (en) 2023-06-12 2025-12-03 Lymphotoxin receptor agonist binding proteins
JOJO/P/2025/0305A JOP20250305A1 (ar) 2023-06-12 2025-12-11 البروتينات الرابطة المنشطة لمستقبل الليمفوتوكسين بيتا

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12
US63/472,565 2023-06-12

Publications (2)

Publication Number Publication Date
WO2024258870A2 WO2024258870A2 (fr) 2024-12-19
WO2024258870A8 true WO2024258870A8 (fr) 2025-12-11

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033443 Pending WO2024258870A2 (fr) 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine

Country Status (11)

Country Link
KR (1) KR20260025131A (fr)
CN (1) CN121399157A (fr)
AR (1) AR132931A1 (fr)
AU (1) AU2024305352A1 (fr)
CL (1) CL2025003919A1 (fr)
IL (1) IL325097A (fr)
JO (1) JOP20250305A1 (fr)
PE (1) PE20260306A1 (fr)
TW (1) TW202506733A (fr)
UY (1) UY40783A (fr)
WO (1) WO2024258870A2 (fr)

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2004013180A2 (fr) 2002-08-01 2004-02-12 Immunomedics, Inc. Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
EP1899477A4 (fr) 2005-07-01 2010-01-20 Medimmune Inc Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
CA2645097C (fr) 2006-03-10 2019-09-17 Wyeth Anticorps anti-5t4 et leurs utilisations
EP2418223A3 (fr) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice
KR101136262B1 (ko) 2007-04-17 2012-07-05 임클론 엘엘씨 ＰＤＧＦＲβ-특이적 억제제
JP5868593B2 (ja) 2007-07-17 2016-02-24 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体
WO2009018386A1 (fr) 2007-07-31 2009-02-05 Medimmune, Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
JP5591712B2 (ja) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
JP2011517320A (ja) 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP3702371B1 (fr) 2009-03-25 2022-11-02 Genentech, Inc. Anticorps anti-fgfr3 et procédés d'utilisation associés
EP2236517A1 (fr) 2009-03-31 2010-10-06 Takara Bio, Inc. Anticorps monoclonal à fragment anti-fibronectine
EP2432824A4 (fr) 2009-05-21 2013-09-11 Tamarisk Technologies L L C Matériaux de construction à base d'alginate
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
RU2570554C2 (ru) 2009-08-31 2015-12-10 Роше Гликарт Аг Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
ES2993335T3 (en) 2010-03-10 2024-12-27 Genmab As Monoclonal antibodies against c-met
CA2796180A1 (fr) 2010-04-15 2011-10-20 Alper Biotech, Llc Anticorps monoclonaux contre antigenes her2 et leurs utilisations
WO2011134060A1 (fr) 2010-04-27 2011-11-03 National Research Council Of Canada Anticorps à domaine unique anti-icam-1 et leurs utilisations
WO2011139375A1 (fr) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
CN103068850A (zh) 2010-05-26 2013-04-24 明尼苏达大学评议会 单链可变片段抗-cd133抗体及其用途
CA3051311A1 (fr) 2010-05-27 2011-12-01 Genmab A/S Anticorps monoclonaux contre her2
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
KR20130048242A (ko) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
CA2805035A1 (fr) 2010-07-22 2012-01-26 Glaxosmithkline Biologicals S.A. Nouvelles proteines de liaison a un antigene
EP2714742A1 (fr) 2011-06-03 2014-04-09 CT Atlantic Ltd. Anticorps se liant à mage a3
CN107011439B (zh) 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
EP2548891A1 (fr) 2011-07-18 2013-01-23 Universiteit Maastricht Anticorps monoclonal humain contre la subunité gamma du récepteur de l'acétylcholine pour une utilisation dans le traitement du rhabdomyosarcome
US9428577B2 (en) 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
AU2013347962B2 (en) 2012-11-21 2018-10-25 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
CA2893378A1 (fr) 2012-12-07 2014-06-12 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-folr1
FI2953971T3 (fi) 2013-02-07 2023-04-27 Csl Ltd Il-11r-sitojaproteiineja ja niiden käyttöjä
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
SI3030581T1 (sl) 2013-08-07 2021-07-30 Affimed Gmbh Mesta za vezavo na protitelo, ki so specifična za EGFRVIII
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
US9840565B2 (en) 2014-05-14 2017-12-12 Hoffmann-La Roche Inc. HER1 antigen binding proteins binding to the beta-hairpin of HER1
CA2950602C (fr) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Anticorps monoclonal humain contre le ganglioside gd2
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
WO2016154623A2 (fr) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps monoclonaux anti-cd133 et compositions et méthodes associées
EP3307784B1 (fr) 2015-06-10 2021-12-22 National Research Council of Canada Anticorps spécifiques de l'anhydrase carbonique ix et leurs utilisations
AU2016283133A1 (en) 2015-06-24 2018-01-04 Eureka Therapeutics, Inc. Constructs targeting NY-ESO-1 peptide/MHC complexes and uses thereof
KR20190040320A (ko) 2016-08-29 2019-04-17 리제너론 파아마슈티컬스, 인크. 항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법
HRP20221202T1 (hr) 2016-09-23 2022-12-09 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antitijela
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
KR20200059249A (ko) 2017-09-21 2020-05-28 유엠씨 우트레크트 홀딩 비.브이. 신경아세포종의 치료를 위한 항-gd2 항체
SG11202003652QA (en) 2017-10-27 2020-05-28 Univ New York Anti-galectin-9 antibodies and uses thereof
EP3728317A2 (fr) 2017-12-21 2020-10-28 F. Hoffmann-La Roche AG Anticorps se liant à hla-a2/wt1
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3796983A2 (fr) 2018-05-23 2021-03-31 Pfizer Inc. Anticorps spécifiques de gucy2c et leurs utilisations
EP3841124A4 (fr) 2018-06-29 2022-03-23 ApitBio, Inc. Anticorps anti-l1cam et leurs utilisations
IL280467B2 (en) 2018-08-03 2025-03-01 Amgen Res Munich Gmbh Antibody constructs for CLDN18.2 and CD3
EP3893930A4 (fr) 2018-10-15 2022-08-24 Board of Regents, The University of Texas System Anticorps monoclonaux dirigés contre la dickkopf3 humaine et leurs utilisations
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도

Also Published As

Publication number Publication date
UY40783A (es) 2024-12-31
AU2024305352A1 (en) 2025-12-04
AR132931A1 (es) 2025-08-13
PE20260306A1 (es) 2026-02-11
KR20260025131A (ko) 2026-02-23
CN121399157A (zh) 2026-01-23
IL325097A (en) 2026-02-01
WO2024258870A2 (fr) 2024-12-19
JOP20250305A1 (ar) 2025-12-11
TW202506733A (zh) 2025-02-16
CL2025003919A1 (es) 2026-01-23

Similar Documents

Publication Publication Date Title
PL4069686T3 (pl) Agonista receptora glp-1
EP3893889B8 (fr) Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation
EP4055037A4 (fr) Composés de liaison à il-2r beta gamma c
EP4095149A4 (fr) Triple agoniste pour récepteur du peptide-1 type glucagon, récepteur du glucagon, et récepteur du polypeptide inhibiteur gastrique
MA55529A (fr) Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
EP4019524A4 (fr) Composé agoniste du récepteur thr-bêta hétérocyclique, son procédé de préparation et son utilisation
CA3265218A1 (fr) Protéines de fusion de récepteurs de lymphocytes t spécifiques de mage a4
EP4159722A4 (fr) Procédé de préparation d'agoniste du récepteur glp-1
EP4119555A4 (fr) Agoniste du récepteur glp-1, composition pharmaceutique le comprenant et son procédé de préparation
AU2024305352A1 (en) Lymphotoxin beta receptor agonist binding proteins
CA3295009A1 (fr) Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
EP4144757A4 (fr) Agoniste double du récepteur du glp-1 et du glucagon à action prolongée
CA3267339A1 (fr) Anticorps agonistes de pd-1
EP3992718A4 (fr) Composition de résine liante destinée à un toner
CA3264024A1 (fr) Antagonistes du récepteur du peptide-1 de type glucagon
HK40106103A (en) Thyroid hormone receptor beta agonist compounds
CA3275875A1 (fr) Protéines de liaison au récepteur de la transferrine
HK40074189A (en) Thyroid hormone receptor beta agonist compounds
CA3296481A1 (fr) Polythérapie avec des agonistes du récepteur bêta de la lymphotoxine ciblant fap
CA3276371A1 (fr) Agonistes du récepteur de la galanine-2
AU2021901129A0 (en) Antigen binding proteins for binding dysfunctional P2X7 receptor
CA3275190A1 (fr) Formulations d'agoniste de récepteur d'hormone inhalable
HK40108078A (en) Fusion protein containing improved glp-1 receptor agonist and uses
HK40108106A (en) Polymorph as thyroid hormone receptor agonists and use thereof
HK40122612A (en) Glucocorticoid receptor agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24741027

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: AU2024305352

Country of ref document: AU

Ref document number: 827438

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 827438

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 325097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2024305352

Country of ref document: AU

Date of ref document: 20240611

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CN202480038870X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: P2025-04030

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 2501008501

Country of ref document: TH

Ref document number: 202517125869

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/015224

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025027542

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: DZP2025001884

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 202593502

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 202517125869

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 325097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 1020267000619

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000619

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 2024741027

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 11202508343V

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508343V

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: MX/A/2025/015224

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: 1020267000619

Country of ref document: KR